Navigation Links
Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
Date:4/14/2008

ble G2 arrest and rapid apoptosis. SNS-595's targeted DNA-topoisomerase II interactions may contribute to the broad therapeutic window observed in patients treated with SNS-595.

In a translational research study designed to evaluate SNS-595's activity in primary patient samples of breast and ovarian cancers and acute myeloid leukemia against other agents, SNS-595 demonstrated potent activity and compared favorably with doxorubicin, etoposide and platinum therapy at clinically relevant concentrations. SNS-595 is not a P-glycoprotein substrate and its activity is independent of the p53 family. This finding is noteworthy, as high or increased expression of P-glycoprotein is a common form of drug resistance. In addition, the activity of many cancer agents requires functional p53 family members, and p53 mutations or deletions are also a frequent cause of drug resistance. Based on these findings, evidence from prior nonclinical studies in drug-resistant tumor models and the objective clinical responses observed to date among patients who have failed prior anthracycline-based therapies, SNS-595 may be active in settings where other topoisomerase poisons are no longer effective. These findings support the ongoing clinical trials in AML and ovarian cancer, and indicate that SNS-595 may also be well-suited to the treatment of breast cancer.

In a third set of studies reported today, Sunesis researchers profiled the potential relationship between SNS-595 activity and DNA repair pathways. Since SNS-595 causes double-strand breaks, the integrity of DNA repair pathways could impact cell sensitivity to SNS-595. Identification of the role of various DNA repair pathways may contribute to the identification of biomarkers for patient stratification. Researchers found that the DNA damage induced by SNS-595 is repaired by homologous recombination repair (HRR), and that cells deficient in HRR have greater sensitivity to SNS-595. Breast and ovarian cancers with BRCA mutations
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
2. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
6. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
7. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
8. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... York City, NY (PRWEB) August 01, 2014 ... for two incomes, and the convenience of processed, microwavable dinners, ... epidemic. Diet Doc does not offer patients a mere quick ... about helping everyone, in any part of the country, get ... that if they offer patients the tools and education on ...
(Date:8/1/2014)... Pompano Beach, FL (PRWEB) August 01, 2014 ... capsules, announced today the opening of a new ... Canada. , The company announced expansion plans last ... products. According to Dale Martin, General Manager, “KCAPS® ... around the world.” He added that: “Compared to ...
(Date:8/1/2014)... St. Christopher's Hospital for Children announced that they ... with Ed Begley Jr, airing later this year 2014, ... St. Christopher's Hospital for Children offers a wide range ... 21 years of age. With over 220 pediatric specialists, ... autism and childhood obesity. , “St. Christopher’s is ...
(Date:8/1/2014)... 01, 2014 A new study ... carbohydrates may contribute to the development of colorectal cancer ... disease. The study was authored by Alberto Martin of ... to cause intestinal cells to multiply and create tumors ... cancer. , “What’s interesting about this study,” said ...
(Date:8/1/2014)... For many people, forgetfulness becomes more ... within the normal range, slips that seem new or ... This merits a closer look, not a panic attack, ... Harvard Men's Health Watch . , "We don't ... their keys are they are on the path to ...
Breaking Medicine News(10 mins):Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Carbs May Contribute to Colon Cancer 2Health News:Worried About Changes in Your Memory? It's Worth A Closer Look, From the August 2014 Harvard Men's Health Watch 2
... brain scans to try and study the biology of dread. ... brain pays to the expected pain // determines and whether ... that simple diversions could alleviate the misery. ,The ... new field called neuroeconomics that uses brain imaging to try ...
... Baeg Moon-hong. He is a senior researcher at the Korea ... was show cased in an exhibition at the Seoul Education ... meters tall. The special features are that it can understand ... expressions. , The first android was made by ...
... the shaking leg syndrome is a common type of disorder in ... For the first time Europe has approved the drug to be ... aches and pains. Statistics show that about 10% of the people ... by the European Medicines Agency. As of now it is used ...
... Health conscious people here lawyers in California have sued PepsiCo ... benzene//., ,The drink in question is Pepsi Twist drink, ... three' soft drinks firms has been drawn into a legal ... the lawsuit, "Pepsi Twist has been falsely promoted as a ...
... the Supreme Court Friday reversed an earlier order directing ... all-India basis// for scheduled castes and scheduled tribes candidates ... ,A bench of judges K.G. Balakrishnan, A.R. Lakshmanan ... General Gopal Subramaniam that enforcing the 10 percent quota ...
... kid of Orissa, declared that his health is normal. // ... up after he ran an astounding 65km earlier this week. ... at Bhubaneswar for a medical check up on the orders ... coach Biranchi Das was exploiting the boy for his personal ...
Cached Medicine News:Health News:Supreme Court Quashed Reservation Quotas For PG Medical Courses 2Health News:Marathon Kid Budhia’s Health Not Compromise 2
(Date:8/1/2014)... , Aug. 1, 2014 MGC ... technologies company, announced today that it has completed ... manufacturer of cardiorespiratory diagnostic products based in Sorinnes, ... has served the European cardiorespiratory diagnostics market since ... revenues of approximately €4.7 million ($6.3 million) and ...
(Date:8/1/2014)... , Aug. 1, 2014  NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank , Chief Executive ... present at the 34 th Annual Canaccord Genuity Growth ... MA , on Wednesday, August 13 th at ... made available at http://ir.nxstage.com/ .  About ...
(Date:8/1/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced ... evaluating ISIS-SMN Rx in infants with spinal muscular ... mortality. Isis plans to dose the first infant in ... time Isis will earn an $18 million milestone payment ... study, ENDEAR, is the first of several planned studies ...
Breaking Medicine Technology:MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5
... - First prospective biomarker trial in non-small cell ... /PRNewswire-FirstCall/ -- Response,Genetics, Inc. today announced that positive ... issue of the Journal of Clinical,Oncology suggests that ... in patient biopsies,with advanced non-small cell lung cancer ...
... been,specifically designed by scientists to be safe to normal ... a preliminary study,researchers said today at the ESMO Conference ... type of herpes simplex virus,modified so that it selectively ... "It doesn't replicate in normal, healthy cells, so our ...
Cached Medicine Technology:Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4MediGene Announces Cancer-Fighting Virus Shows Promise in Early,Clinical Trial 2MediGene Announces Cancer-Fighting Virus Shows Promise in Early,Clinical Trial 3MediGene Announces Cancer-Fighting Virus Shows Promise in Early,Clinical Trial 4MediGene Announces Cancer-Fighting Virus Shows Promise in Early,Clinical Trial 5
...
...
EDM Lumbar Drainage Kit with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in the lumen....
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Medicine Products: